Oppenheimer analyst Jeff Jones reiterated a Buy rating on Alumis Inc. (ALMS – Research Report) today and set a price target of $26.00. The ...

H.C. Wainwright lowered the firm’s price target on Alumis (ALMS) to $15 from $19 and keeps a Buy rating on the shares following the Q4 report.

Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated ...

Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize ...

Pliant and Acelyrin adopt poison pill measures to counter activist investor Kevin Tang's stock accumulation, aiming to ...

SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to ...

The move by Acelyrin’s board comes as the venture capital firm has taken larger and larger stakes in the company in an ...

HC Wainwright reissued their buy rating on shares of Alumis (NASDAQ:ALMS – Free Report) in a report published on Monday,Benzinga reports. They currently have a $19.00 price objective on the stock. A ...

Alumis Inc. (NASDAQ:ALMS – Get Free Report) has received a consensus rating of “Buy” from the nine analysts that are presently covering the firm, Marketbeat Ratings reports.Seven investment ...

Alumis announced positive Phase 2 OLE results for ESK-001, a TYK2 inhibitor for moderate-to-severe plaque psoriasis, showing sustained clinical improvements. Alumis Inc. has announced positive 52 ...